These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19584316)

  • 1. Aneuploidy: from a physiological mechanism of variance to Down syndrome.
    Dierssen M; Herault Y; Estivill X
    Physiol Rev; 2009 Jul; 89(3):887-920. PubMed ID: 19584316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.
    Belichenko PV; Kleschevnikov AM; Salehi A; Epstein CJ; Mobley WC
    J Comp Neurol; 2007 Oct; 504(4):329-45. PubMed ID: 17663443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using mouse models to explore genotype-phenotype relationship in Down syndrome.
    Salehi A; Faizi M; Belichenko PV; Mobley WC
    Ment Retard Dev Disabil Res Rev; 2007; 13(3):207-14. PubMed ID: 17910089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome).
    Roubertoux PL; Carlier M
    Am J Med Genet C Semin Med Genet; 2010 Nov; 154C(4):400-16. PubMed ID: 20981769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models of cognitive disorders in trisomy 21: a review.
    Sérégaza Z; Roubertoux PL; Jamon M; Soumireu-Mourat B
    Behav Genet; 2006 May; 36(3):387-404. PubMed ID: 16523244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways.
    Rachidi M; Lopes C
    Eur J Paediatr Neurol; 2008 May; 12(3):168-82. PubMed ID: 17933568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome.
    Rachidi M; Lopes C
    Am J Intellect Dev Disabil; 2010 Mar; 115(2):83-112. PubMed ID: 20441388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms.
    Rachidi M; Lopes C
    Neurosci Res; 2007 Dec; 59(4):349-69. PubMed ID: 17897742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On dendrites in Down syndrome and DS murine models: a spiny way to learn.
    Benavides-Piccione R; Ballesteros-Yáñez I; de Lagrán MM; Elston G; Estivill X; Fillat C; Defelipe J; Dierssen M
    Prog Neurobiol; 2004 Oct; 74(2):111-26. PubMed ID: 15518956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome mouse models are looking up.
    Reeves RH
    Trends Mol Med; 2006 Jun; 12(6):237-40. PubMed ID: 16677859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic mechanisms involved in the phenotype of Down syndrome.
    Patterson D
    Ment Retard Dev Disabil Res Rev; 2007; 13(3):199-206. PubMed ID: 17910086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 21 and down syndrome: from genomics to pathophysiology.
    Antonarakis SE; Lyle R; Dermitzakis ET; Reymond A; Deutsch S
    Nat Rev Genet; 2004 Oct; 5(10):725-38. PubMed ID: 15510164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of Down syndrome.
    Dutta S; Nandagopal K; Gangopadhyay PK; Mukhopadhyay K
    Indian Pediatr; 2005 Apr; 42(4):339-44. PubMed ID: 15876595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.
    Olson LE; Roper RJ; Sengstaken CL; Peterson EA; Aquino V; Galdzicki Z; Siarey R; Pletnikov M; Moran TH; Reeves RH
    Hum Mol Genet; 2007 Apr; 16(7):774-82. PubMed ID: 17339268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "gene dosage effect" hypothesis versus the "amplified developmental instability" hypothesis in Down syndrome.
    Pritchard MA; Kola I
    J Neural Transm Suppl; 1999; 57():293-303. PubMed ID: 10666684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitfalls and hopes in Down syndrome therapeutic approaches: in the search for evidence-based treatments.
    Dierssen M; Ortiz-Abalia J; Arqué G; de Lagrán MM; Fillat C
    Behav Genet; 2006 May; 36(3):454-68. PubMed ID: 16520905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down syndrome--a disruption of homeostasis.
    Shapiro BL
    Am J Med Genet; 1983 Feb; 14(2):241-69. PubMed ID: 6220605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental consequences of autosomal aneuploidy in mammals.
    Gearhart JD; Oster-Granite ML; Reeves RH; Coyle JT
    Dev Genet; 1987; 8(4):249-65. PubMed ID: 2971493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-dosage effect on chromosome 21 transcriptome in trisomy 21: implication in Down syndrome cognitive disorders.
    Kahlem P
    Behav Genet; 2006 May; 36(3):416-28. PubMed ID: 16557362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down syndrome gene dosage imbalance on cerebellum development.
    Moldrich RX; Dauphinot L; Laffaire J; Rossier J; Potier MC
    Prog Neurobiol; 2007 Jun; 82(2):87-94. PubMed ID: 17408845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.